117 related articles for article (PubMed ID: 29526801)
1. BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy.
Oing C; Tennstedt P; Simon R; Volquardsen J; Borgmann K; Bokemeyer C; Petersen C; Dikomey E; Rothkamm K; Mansour WY
Cancer Lett; 2018 Jun; 423():60-70. PubMed ID: 29526801
[TBL] [Abstract][Full Text] [Related]
2. A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer.
Köcher S; Beyer B; Lange T; Nordquist L; Volquardsen J; Burdak-Rothkamm S; Schlomm T; Petersen C; Rothkamm K; Mansour WY
Int J Cancer; 2019 Apr; 144(7):1685-1696. PubMed ID: 30478958
[TBL] [Abstract][Full Text] [Related]
3. Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 and PARP2 with DNA double-strand break repair pathways.
Ghosh R; Roy S; Kamyab J; Danzter F; Franco S
DNA Repair (Amst); 2016 Sep; 45():56-62. PubMed ID: 27373144
[TBL] [Abstract][Full Text] [Related]
4. The absence of Ku but not defects in classical non-homologous end-joining is required to trigger PARP1-dependent end-joining.
Mansour WY; Borgmann K; Petersen C; Dikomey E; Dahm-Daphi J
DNA Repair (Amst); 2013 Dec; 12(12):1134-42. PubMed ID: 24210699
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin.
Robert C; Nagaria PK; Pawar N; Adewuyi A; Gojo I; Meyers DJ; Cole PA; Rassool FV
Leuk Res; 2016 Jun; 45():14-23. PubMed ID: 27064363
[TBL] [Abstract][Full Text] [Related]
6. Nuclear PTEN interferes with binding of Ku70 at double-strand breaks through post-translational poly(ADP-ribosyl)ation.
Guan J; Zhao Q; Mao W
Biochim Biophys Acta; 2016 Dec; 1863(12):3106-3115. PubMed ID: 27741411
[TBL] [Abstract][Full Text] [Related]
7. IER5 is involved in DNA Double-Strand Breaks Repair in Association with PAPR1 in Hela Cells.
Yu XP; Wu YM; Liu Y; Tian M; Wang JD; Ding KK; Ma T; Zhou PK
Int J Med Sci; 2017; 14(12):1292-1300. PubMed ID: 29104487
[TBL] [Abstract][Full Text] [Related]
8. Targeting of β1 integrins impairs DNA repair for radiosensitization of head and neck cancer cells.
Dickreuter E; Eke I; Krause M; Borgmann K; van Vugt MA; Cordes N
Oncogene; 2016 Mar; 35(11):1353-62. PubMed ID: 26073085
[TBL] [Abstract][Full Text] [Related]
9. Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property.
Prasad CB; Prasad SB; Yadav SS; Pandey LK; Singh S; Pradhan S; Narayan G
Sci Rep; 2017 Oct; 7(1):12876. PubMed ID: 28993682
[TBL] [Abstract][Full Text] [Related]
10. BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma.
Herbert K; Binet R; Lambert JP; Louphrasitthiphol P; Kalkavan H; Sesma-Sanz L; Robles-Espinoza CD; Sarkar S; Suer E; Andrews S; Chauhan J; Roberts ND; Middleton MR; Gingras AC; Masson JY; Larue L; Falletta P; Goding CR
Genes Dev; 2019 Mar; 33(5-6):310-332. PubMed ID: 30804224
[TBL] [Abstract][Full Text] [Related]
11. PARP1-siRNA suppresses human prostate cancer cell growth and progression.
Lai Y; Kong Z; Zeng T; Xu S; Duan X; Li S; Cai C; Zhao Z; Wu W
Oncol Rep; 2018 Apr; 39(4):1901-1909. PubMed ID: 29393407
[TBL] [Abstract][Full Text] [Related]
12. Regulation of DNA repair in the absence of classical non-homologous end joining.
Kang YJ; Yan CT
DNA Repair (Amst); 2018 Aug; 68():34-40. PubMed ID: 29929045
[TBL] [Abstract][Full Text] [Related]
13. Rational combination therapy for hepatocellular carcinoma with PARP1 and DNA-PK inhibitors.
Wang C; Tang H; Geng A; Dai B; Zhang H; Sun X; Chen Y; Qiao Z; Zhu H; Yang J; Chen J; He Q; Qin N; Xie J; Tan R; Wan X; Gao S; Jiang Y; Sun FL; Mao Z
Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26356-26365. PubMed ID: 33020270
[TBL] [Abstract][Full Text] [Related]
14. Bcl2 negatively regulates DNA double-strand-break repair through a nonhomologous end-joining pathway.
Wang Q; Gao F; May WS; Zhang Y; Flagg T; Deng X
Mol Cell; 2008 Feb; 29(4):488-98. PubMed ID: 18313386
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of PARP1-dependent end-joining contributes to Olaparib-mediated radiosensitization in tumor cells.
Kötter A; Cornils K; Borgmann K; Dahm-Daphi J; Petersen C; Dikomey E; Mansour WY
Mol Oncol; 2014 Dec; 8(8):1616-25. PubMed ID: 25028150
[TBL] [Abstract][Full Text] [Related]
16. Alternative NHEJ Pathway Components Are Therapeutic Targets in High-Risk Neuroblastoma.
Newman EA; Lu F; Bashllari D; Wang L; Opipari AW; Castle VP
Mol Cancer Res; 2015 Mar; 13(3):470-82. PubMed ID: 25563294
[TBL] [Abstract][Full Text] [Related]
17. BCL2 suppresses PARP1 function and nonapoptotic cell death.
Dutta C; Day T; Kopp N; van Bodegom D; Davids MS; Ryan J; Bird L; Kommajosyula N; Weigert O; Yoda A; Fung H; Brown JR; Shapiro GI; Letai A; Weinstock DM
Cancer Res; 2012 Aug; 72(16):4193-203. PubMed ID: 22689920
[TBL] [Abstract][Full Text] [Related]
18. DNA-PKcs expression predicts response to radiotherapy in prostate cancer.
Bouchaert P; Guerif S; Debiais C; Irani J; Fromont G
Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1179-85. PubMed ID: 22494583
[TBL] [Abstract][Full Text] [Related]
19. c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias.
Muvarak N; Kelley S; Robert C; Baer MR; Perrotti D; Gambacorti-Passerini C; Civin C; Scheibner K; Rassool FV
Mol Cancer Res; 2015 Apr; 13(4):699-712. PubMed ID: 25828893
[TBL] [Abstract][Full Text] [Related]
20. Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
Bi Y; Verginadis II; Dey S; Lin L; Guo L; Zheng Y; Koumenis C
Gynecol Oncol; 2018 Sep; 150(3):534-544. PubMed ID: 30025822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
